Cytek Biosciences, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Cytek Biosciences reported an adjusted loss of 5 cents per share for the quarter ended September 30, compared with a 4-cent loss a year earlier and analyst expectations for a 7-cent loss. Revenue rose 1.8% year over year to $53.23 million, above the $52.80 million expected.

Confirmed

Global impact / market context

The smaller-than-expected per-share loss and revenue above forecasts suggest the quarter’s sales and costs came in better than analysts anticipated. However, the company still reported a $6.1 million loss, so investors may focus on whether revenue growth can continue and help reduce losses.

Analyst inference

Analyst earnings estimates had fallen about 16.7% over three months, though none changed in the latest 30 days. The average rating was “buy,” but the median 12-month price target of $5.00 was below the last close of $5.96.

Confirmed

What to watch

1. Future quarterly revenue growth may show whether the 1.8% increase can persist and provide more sales to cover operating costs and narrow the reported loss. Analyst inference
2. Watch whether the company’s reported loss per share improves in coming quarters; sustained improvement would indicate progress toward reducing the gap between revenue and costs. Analyst inference
3. Analysts’ next earnings estimate revisions could indicate whether expectations recover after the earlier decline; no revisions were reported in the 30 days covered. Analyst inference

Evidence

• Original source link unavailable